vs

Side-by-side financial comparison of Marqeta, Inc. (MQ) and Vericel Corp (VCEL). Click either name above to swap in a different company.

Marqeta, Inc. is the larger business by last-quarter revenue ($172.1M vs $92.9M, roughly 1.9× Vericel Corp). On growth, Marqeta, Inc. posted the faster year-over-year revenue change (26.7% vs 23.3%). Marqeta, Inc. produced more free cash flow last quarter ($53.2M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 20.8%).

Marqeta, Inc. operates a cloud-native open API platform for modern card issuing and digital payment processing. Its solutions empower fintech startups, large retailers, and enterprise clients to launch customized physical and virtual payment cards, as well as embedded finance products across global consumer and commercial markets.

Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.

MQ vs VCEL — Head-to-Head

Bigger by revenue
MQ
MQ
1.9× larger
MQ
$172.1M
$92.9M
VCEL
Growing faster (revenue YoY)
MQ
MQ
+3.5% gap
MQ
26.7%
23.3%
VCEL
More free cash flow
MQ
MQ
$40.3M more FCF
MQ
$53.2M
$12.8M
VCEL
Faster 2-yr revenue CAGR
VCEL
VCEL
Annualised
VCEL
34.6%
20.8%
MQ

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MQ
MQ
VCEL
VCEL
Revenue
$172.1M
$92.9M
Net Profit
$23.2M
Gross Margin
69.7%
78.7%
Operating Margin
-4.8%
24.1%
Net Margin
25.0%
Revenue YoY
26.7%
23.3%
Net Profit YoY
17.3%
EPS (diluted)
$0.46

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MQ
MQ
VCEL
VCEL
Q4 25
$172.1M
$92.9M
Q3 25
$163.3M
$67.5M
Q2 25
$150.4M
$63.2M
Q1 25
$139.1M
$52.6M
Q4 24
$135.8M
$75.4M
Q3 24
$128.0M
$57.9M
Q2 24
$125.3M
$52.7M
Q1 24
$118.0M
$51.3M
Net Profit
MQ
MQ
VCEL
VCEL
Q4 25
$23.2M
Q3 25
$-3.6M
$5.1M
Q2 25
$-647.0K
$-553.0K
Q1 25
$-8.3M
$-11.2M
Q4 24
$19.8M
Q3 24
$-28.6M
$-901.0K
Q2 24
$119.1M
$-4.7M
Q1 24
$-36.1M
$-3.9M
Gross Margin
MQ
MQ
VCEL
VCEL
Q4 25
69.7%
78.7%
Q3 25
70.1%
73.5%
Q2 25
69.2%
73.7%
Q1 25
71.0%
69.0%
Q4 24
72.3%
77.6%
Q3 24
70.4%
71.9%
Q2 24
63.3%
69.5%
Q1 24
71.3%
68.9%
Operating Margin
MQ
MQ
VCEL
VCEL
Q4 25
-4.8%
24.1%
Q3 25
-6.4%
5.1%
Q2 25
-6.1%
-3.2%
Q1 25
-13.3%
-24.3%
Q4 24
-27.6%
24.5%
Q3 24
-33.0%
-4.3%
Q2 24
83.9%
-11.5%
Q1 24
-42.3%
-10.7%
Net Margin
MQ
MQ
VCEL
VCEL
Q4 25
25.0%
Q3 25
-2.2%
7.5%
Q2 25
-0.4%
-0.9%
Q1 25
-5.9%
-21.4%
Q4 24
26.3%
Q3 24
-22.4%
-1.6%
Q2 24
95.1%
-8.9%
Q1 24
-30.6%
-7.5%
EPS (diluted)
MQ
MQ
VCEL
VCEL
Q4 25
$0.46
Q3 25
$0.10
Q2 25
$-0.01
Q1 25
$-0.23
Q4 24
$0.40
Q3 24
$-0.02
Q2 24
$-0.10
Q1 24
$-0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MQ
MQ
VCEL
VCEL
Cash + ST InvestmentsLiquidity on hand
$709.4M
$137.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$762.0M
$354.6M
Total Assets
$1.5B
$488.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MQ
MQ
VCEL
VCEL
Q4 25
$709.4M
$137.5M
Q3 25
$747.2M
$135.4M
Q2 25
$732.7M
$116.9M
Q1 25
$830.9M
$112.9M
Q4 24
$923.0M
$116.2M
Q3 24
$886.4M
$101.7M
Q2 24
$924.7M
$102.5M
Q1 24
$970.4M
$110.6M
Stockholders' Equity
MQ
MQ
VCEL
VCEL
Q4 25
$762.0M
$354.6M
Q3 25
$839.2M
$321.9M
Q2 25
$843.4M
$306.8M
Q1 25
$987.3M
$295.5M
Q4 24
$1.1B
$292.0M
Q3 24
$1.1B
$257.5M
Q2 24
$1.1B
$243.0M
Q1 24
$1.2B
$233.9M
Total Assets
MQ
MQ
VCEL
VCEL
Q4 25
$1.5B
$488.0M
Q3 25
$1.5B
$453.3M
Q2 25
$1.2B
$435.6M
Q1 25
$1.3B
$424.6M
Q4 24
$1.5B
$432.7M
Q3 24
$1.4B
$390.4M
Q2 24
$1.5B
$376.8M
Q1 24
$1.6B
$356.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MQ
MQ
VCEL
VCEL
Operating Cash FlowLast quarter
$53.3M
$15.0M
Free Cash FlowOCF − Capex
$53.2M
$12.8M
FCF MarginFCF / Revenue
30.9%
13.8%
Capex IntensityCapex / Revenue
0.1%
2.4%
Cash ConversionOCF / Net Profit
0.65×
TTM Free Cash FlowTrailing 4 quarters
$160.5M
$24.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MQ
MQ
VCEL
VCEL
Q4 25
$53.3M
$15.0M
Q3 25
$86.8M
$22.1M
Q2 25
$12.5M
$8.2M
Q1 25
$10.0M
$6.6M
Q4 24
$24.8M
$22.2M
Q3 24
$7.3M
$10.2M
Q2 24
$25.7M
$18.5M
Q1 24
$426.0K
$7.2M
Free Cash Flow
MQ
MQ
VCEL
VCEL
Q4 25
$53.2M
$12.8M
Q3 25
$86.4M
$19.5M
Q2 25
$12.2M
$81.0K
Q1 25
$8.7M
$-7.6M
Q4 24
$24.7M
$8.5M
Q3 24
$7.1M
$-9.2M
Q2 24
$24.7M
$1.8M
Q1 24
$-765.0K
$-6.8M
FCF Margin
MQ
MQ
VCEL
VCEL
Q4 25
30.9%
13.8%
Q3 25
52.9%
28.8%
Q2 25
8.1%
0.1%
Q1 25
6.3%
-14.5%
Q4 24
18.2%
11.2%
Q3 24
5.5%
-15.9%
Q2 24
19.7%
3.4%
Q1 24
-0.6%
-13.3%
Capex Intensity
MQ
MQ
VCEL
VCEL
Q4 25
0.1%
2.4%
Q3 25
0.2%
3.9%
Q2 25
0.2%
12.9%
Q1 25
0.9%
27.0%
Q4 24
0.0%
18.3%
Q3 24
0.1%
33.5%
Q2 24
0.8%
31.8%
Q1 24
1.0%
27.3%
Cash Conversion
MQ
MQ
VCEL
VCEL
Q4 25
0.65×
Q3 25
4.35×
Q2 25
Q1 25
Q4 24
1.12×
Q3 24
Q2 24
0.22×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MQ
MQ

Platform Service Revenue Net$163.4M95%
Other Services Revenue$8.8M5%

VCEL
VCEL

MACI Implants And Kits$84.1M90%
Other$8.8M10%

Related Comparisons